First Global Downgrades Teva Pharma (TEVA) to Market Perform, Poor Laquinimod Phase III Drug Trial Results
Tweet Send to a Friend
First Global downgraded shares of Teva Pharma (NASDAQ: TEVA) to a Market Perform rating following the release of its two ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
